The development of neuropathic syndromes is an important, dose limiting side effect of anticancer agents like platinum derivates, taxanes and vinca alkaloids. The causes of neurotoxicity are still unclear but the impairment of the oxidative equilibrium is strictly related to pain. Two intracellular organelles, mitochondria and peroxisomes cooperate to the maintaining of the redox cellular state. Whereas a relationship between chemotherapy-dependent mitochondrial alteration and neuropathy has been established, the role of peroxisome is poor explored. In order to study the mechanisms of oxaliplatin-induced neurotoxicity, peroxisomal involvement was evaluated in vitro and in vivo. In primary rat astrocyte cell culture, oxaliplatin (10 mM for 48 h or 1 mM for 5 days) increased the number of peroxisomes, nevertheless expression and functionality of catalase, the most important antioxidant defense enzyme in mammalian peroxisomes, were significantly reduced. Five day incubation with the selective Peroxisome Proliferator Activated Receptor-c (PPAR-c) antagonist G3335 (30 mM) induced a similar peroxisomal impairment suggesting a relationship between PPARc signaling and oxaliplatin neurotoxicity. The PPARc agonist rosiglitazone (10 mM) reduced the harmful effects induced both by G3335 and oxaliplatin. In vivo, in a rat model of oxaliplatin induced neuropathy, a repeated treatment with rosiglitazone (3 and 10 mg kg21 per os) significantly reduced neuropathic pain evoked by noxious (Paw pressure test) and non-noxious (Cold plate test) stimuli. The behavioral effect paralleled with the prevention of catalase impairment induced by oxaliplatin in dorsal root ganglia. In the spinal cord, catalase protection was showed by the lower rosiglitazone dosage without effect on the astrocyte density increase induced by oxaliplatin. Rosiglitazone did not alter the oxaliplatin-induced mortality of the human colon cancer cell line HT-29. These results highlight the role of peroxisomes in oxaliplatin-dependent nervous damage and suggest PPARc stimulation as a candidate to counteract oxaliplatin neurotoxicity.

Oxaliplatin Neurotoxicity Involves Peroxisome Alterations. PPARc Agonism as Preventive Pharmacological Approach / Zanardelli, M; Micheli, L; Cinci, L; Failli, P; Ghelardini, C; Di Cesare Mannelli, L. - In: PLOS ONE. - ISSN 1932-6203. - STAMPA. - 9:(2014), pp. 0-0. [10.1371/journal.pone.0102758]

Oxaliplatin Neurotoxicity Involves Peroxisome Alterations. PPARc Agonism as Preventive Pharmacological Approach

ZANARDELLI, MATTEO;MICHELI, LAURA;CINCI, LORENZO;FAILLI, PAOLA;GHELARDINI, CARLA;DI CESARE MANNELLI, LORENZO
2014

Abstract

The development of neuropathic syndromes is an important, dose limiting side effect of anticancer agents like platinum derivates, taxanes and vinca alkaloids. The causes of neurotoxicity are still unclear but the impairment of the oxidative equilibrium is strictly related to pain. Two intracellular organelles, mitochondria and peroxisomes cooperate to the maintaining of the redox cellular state. Whereas a relationship between chemotherapy-dependent mitochondrial alteration and neuropathy has been established, the role of peroxisome is poor explored. In order to study the mechanisms of oxaliplatin-induced neurotoxicity, peroxisomal involvement was evaluated in vitro and in vivo. In primary rat astrocyte cell culture, oxaliplatin (10 mM for 48 h or 1 mM for 5 days) increased the number of peroxisomes, nevertheless expression and functionality of catalase, the most important antioxidant defense enzyme in mammalian peroxisomes, were significantly reduced. Five day incubation with the selective Peroxisome Proliferator Activated Receptor-c (PPAR-c) antagonist G3335 (30 mM) induced a similar peroxisomal impairment suggesting a relationship between PPARc signaling and oxaliplatin neurotoxicity. The PPARc agonist rosiglitazone (10 mM) reduced the harmful effects induced both by G3335 and oxaliplatin. In vivo, in a rat model of oxaliplatin induced neuropathy, a repeated treatment with rosiglitazone (3 and 10 mg kg21 per os) significantly reduced neuropathic pain evoked by noxious (Paw pressure test) and non-noxious (Cold plate test) stimuli. The behavioral effect paralleled with the prevention of catalase impairment induced by oxaliplatin in dorsal root ganglia. In the spinal cord, catalase protection was showed by the lower rosiglitazone dosage without effect on the astrocyte density increase induced by oxaliplatin. Rosiglitazone did not alter the oxaliplatin-induced mortality of the human colon cancer cell line HT-29. These results highlight the role of peroxisomes in oxaliplatin-dependent nervous damage and suggest PPARc stimulation as a candidate to counteract oxaliplatin neurotoxicity.
9
0
0
Zanardelli, M; Micheli, L; Cinci, L; Failli, P; Ghelardini, C; Di Cesare Mannelli, L
File in questo prodotto:
File Dimensione Formato  
Oxaliplatin Neurotoxicity Involves Peroxisome Alterations. PPARc Agonism as Preventive Pharmacological Approach.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 4.98 MB
Formato Adobe PDF
4.98 MB Adobe PDF Visualizza/Apri

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2158/963013
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 59
  • ???jsp.display-item.citation.isi??? 59
social impact